The Commission has announced that it has opened an investigation into contractual provisions between the pharmaceutical companies Johnson & Johnson and its Swiss counterpart Novartis. The Commission is examining whether certain contractual agreements have the object or effect of delaying the entry of a generic version of painkiller Fentanyl onto the Dutch market, practices which could be deemed contrary to Article 101 TFEU.